RESEARCH INVENTION JOURNAL OF SCIENTIFIC AND EXPERIMENTAL SCIENCES 6(1):75-80, 2026
©RIJSES Publications
ONLINE ISSN: 1115-618X
PRINT ISSN: 1597-2917
https://doi.org/10.59298/RIJSES/2026/617580

Integrating Toxicology and Traditional Medicine: Herbal Strategies Against Metabolic and Organ-Specific Disorders

Waiswa Arajab

Department of Pharmacy Kampala International University Uganda
Email: arajab.waiswa@studwc.kiu.ac.ug

ABSTRACT

Traditional herbal medicines are widely used to manage metabolic diseases (diabetes, dyslipidaemia, nonalcoholic fatty liver disease) and organ-specific disorders (hepatotoxicity, nephrotoxicity, neurotoxicity, cardiotoxicity). Many phytochemicals demonstrate biologically plausible benefits through antioxidant, anti-inflammatory, metabolic-modulating, and organoprotective mechanisms. However, toxicology concerns intrinsic phytochemical toxicity, contaminants (heavy metals, pesticides), adulteration with pharmaceuticals, dose-dependent pro-oxidant effects, and herb–drug interactions-remain significant barriers to safe integration. This review synthesizes mechanistic rationales for herbal strategies against metabolic and organ-specific disorders, examines representative botanicals and formulations with evidence of benefit, and places toxicological risks in the foreground of translational planning. We propose a framework for integrating toxicology into traditional-medicine practice and research: standardized extracts and quality control, pharmacokinetics and dose-finding, preclinical toxicology screening, herb–drug interaction assessment, targeted clinical trials with mechanistic endpoints, and active pharmacovigilance. Practical recommendations for clinicians, policymakers and researchers include patient screening for vulnerabilities (hepatic or renal impairment, G6PD deficiency, polypharmacy), selecting evidence-grade products, and embedding safety monitoring in routine care. With rigorous toxicology-informed approaches, traditional herbal strategies can be responsibly evaluated and, where appropriate, deployed as adjunctive tools to prevent or mitigate metabolic and organ-specific disorders.

Keywords: Herbal medicine, Toxicology, Metabolic disease, Organ protection, Phytochemicals

INTRODUCTION

Herbal medicines have been integral to human health for centuries and continue to provide essential care for a substantial proportion of the global population, particularly in regions where access to conventional pharmaceuticals is limited or unaffordable [1]. In recent decades, interest in herbal remedies has surged even in industrialized nations, driven by growing recognition of their bioactive constituents and their potential to complement modern therapeutic approaches [2]. This trend is particularly evident in the management of metabolic diseases such as diabetes, obesity, and dyslipidaemia, as well as in organ-specific pathologies including hepatotoxicity, nephrotoxicity, neurotoxicity, and cardiotoxicity [3]. The scientific basis for this renewed attention lies in the multifunctional properties of phytochemicals. Unlike single-target synthetic drugs, many phytochemicals exert pleiotropic effects that simultaneously modulate oxidative stress, inflammation, mitochondrial integrity, and metabolic regulation [4]. Such activities are especially relevant for chronic metabolic and organ disorders, which often arise from complex networks of pathological processes rather than single causal events [5]. For example, diabetes is not only a disease of glucose imbalance but also a condition characterized by low-grade inflammation, mitochondrial dysfunction, and progressive oxidative damage. Similarly, organ injuries induced by drugs or environmental toxins frequently involve overlapping mechanisms of oxidative stress, immune activation, and apoptosis [6]. Despite these promising attributes, the use of herbal medicines is not without challenges. Toxicological issues remain a major concern, as some herbs contain inherently toxic constituents or may become harmful when contaminated, adulterated, or consumed inappropriately [7]. Additionally, interactions with conventional drugs and variability in the quality of herbal preparations raise safety questions [8,9]. These

complexities highlight the necessity of integrating toxicological evaluation into the exploration and application of herbal remedies. Only through such integration can traditional medicine be responsibly aligned with evidence-based healthcare.

Mechanistic rationale for herbal strategies

Herbal interventions relevant to metabolic and organ-specific disorders operate through a variety of conserved biological mechanisms that address the multifactorial nature of these diseases [10]. Antioxidant and redox modulation is one of the most consistently observed actions, with polyphenols, flavonoids, and tannins acting not only as radical scavengers but also as inducers of endogenous antioxidant defenses via the Nrf2/ARE pathway [11]. This dual mechanism helps restore redox balance and protects cells from oxidative injury. Another critical mechanism is anti-inflammatory signaling. By suppressing NF-κB activation and inflammasome pathways, phytochemicals reduce the production of pro-inflammatory cytokines that underlie insulin resistance, tissue fibrosis, and chronic organ injury [12]. Protection of mitochondrial bioenergetics represents a third pillar of herbal action. Compounds such as resveratrol and ginsenosides enhance mitochondrial biogenesis, stabilize membranes, and improve ATP generation, thereby counteracting energy deficits associated with metabolic stress [13].

Metabolic modulation is also central, with agents such as berberine and silymarin improving glucose uptake, enhancing insulin sensitivity, modulating lipid metabolism, and reducing hepatic steatosis [14]. In cases of chronic injury, antifibrotic and antiapoptotic properties are equally important. Some herbs inhibit TGF-β/Smad signaling, reduce extracellular matrix deposition, and prevent programmed cell death, thereby preserving organ architecture and function [15]. Finally, certain phytochemicals support detoxification through metal chelation or induction of phase II enzymes, enhancing the body's capacity to eliminate xenobiotics and environmental toxins [16]. This constellation of mechanisms explains why herbal remedies are attractive in complex disorders where multiple pathogenic nodes converge, and it underscores the importance of evaluating them within a toxicological framework to ensure both efficacy and safety.

Representative botanicals and evidence snapshots

Several botanicals stand out for their relevance in metabolic and organ-specific disorders, supported by preclinical and clinical evidence [17]. Silymarin, derived from milk thistle, remains one of the most widely studied hepatoprotective agents. Its flavonolignans act as antioxidants, membrane stabilizers, and antifibrotic agents. Clinical trials suggest benefit in non-alcoholic fatty liver disease (NAFLD) and toxic hepatitis, though variability in extract quality and dosing complicates reproducibility [18].

Berberine, an isoquinoline alkaloid from Berberis species, exerts significant metabolic effects by activating AMP-activated protein kinase (AMPK) and modulating gut microbiota. It improves glycaemia, lipid profiles, and exhibits anti-inflammatory properties. Preclinical evidence extends its utility to renal and cardiovascular protection, yet its potential to inhibit cytochrome P450 enzymes raises interaction concerns, particularly in polypharmacy settings [19].

Curcumin, the yellow pigment of turmeric, has been intensively investigated for its anti-inflammatory, antioxidant, and metabolic benefits [20]. It shows promise in improving insulin sensitivity, lipid metabolism, and reducing inflammatory markers in metabolic syndrome. Moreover, it mitigates injury in experimental models of liver, kidney, and brain toxicity. A major limitation is its poor oral bioavailability, which has prompted the development of nanoparticle, liposomal, and piperine-enhanced formulations [21,22].

Resveratrol, a stilbene found in grapes and berries, activates SIRT1 and PGC-1α, thereby promoting mitochondrial biogenesis and resilience [23]. While rodent models demonstrate protection against diabetes, cardiovascular dysfunction, and neurodegeneration, translation to humans remains inconsistent, with only modest clinical effects reported.

Other flavonoids such as quercetin and catechins, particularly epigallocatechin gallate (EGCG) from green tea, combine direct radical-scavenging activity with signaling effects, including Nrf2 activation and metal chelation [24]. They have demonstrated metabolic improvements and neuroprotective potential, though concentrated extracts occasionally cause hepatotoxicity, highlighting the importance of dose and formulation.

Additional agents include glycyrrhizin from licorice, which exerts hepatoprotective and immunomodulatory effects but carries a risk of mineralocorticoid side effects such as hypertension and hypokalemia [25]. Nutritional herbs like Moringa and other iron-rich greens provide adjunctive benefits in anemia but require monitoring for contaminants and ensuring bioavailable formulations. Traditional polyherbal formulations, as used in Ayurveda or Traditional Chinese Medicine, may offer synergistic effects, though the complexity of multi-component mixtures poses challenges for standardization, efficacy assessment, and toxicological profiling [26].

Toxicology challenges: sources and consequences

Despite therapeutic promise, herbal medicines present several toxicological challenges [6]. Intrinsic phytochemical toxicity is well documented; for instance, aristolochic acids from Aristolochia species are potent nephrotoxins that

can trigger interstitial fibrosis and renal failure [27]. Similarly, pyrrolizidine alkaloids in some hepatoprotective herbs paradoxically induce liver damage.

Contaminants and adulterants represent a pervasive risk. Heavy metals, pesticides, and microbial toxins may enter the supply chain through poor agricultural and manufacturing practices [28]. In some cases, undeclared pharmaceuticals are deliberately added to enhance apparent efficacy, masking toxicity while increasing the risk of drug–drug interactions [29].

Dose-related paradoxes also exist. Antioxidants such as flavonoids can act as pro-oxidants in the presence of redox-active metals, generating additional reactive oxygen species and exacerbating oxidative injury [30]. This dose-response complexity underlines the importance of carefully designed safety thresholds. Herb-drug interactions form another significant concern [31]. Modulation of cytochrome P450 enzymes, drug transporters, or glucuronidation pathways can alter the pharmacokinetics of prescription medicines. St. John's wort analogues, berberine, and even green tea catechins can influence drug absorption and clearance, sometimes leading to therapeutic failure or toxicity [32]. Certain populations are particularly vulnerable to these risks. Individuals with pre-existing hepatic or renal impairment, pregnant or breastfeeding women, children, and those with genetic predispositions such as G6PD deficiency may face disproportionately high risks [33]. Polypharmacy, common among patients with metabolic and chronic organ-specific disorders, further amplifies the danger of interactions. The consequences of these toxicological challenges are clinically significant, ranging from idiosyncratic liver injury and accelerated nephropathy to neurotoxic reactions or cardiovascular instability [34]. In some cases, toxicity is masked by adulteration, complicating both diagnosis and regulatory oversight. Addressing these issues requires robust quality assurance, transparent labeling, toxicological screening, and education of both clinicians and patients [35].

Application to specific disorders

The integration of phytomedicines into management strategies for specific disorders requires careful alignment with conventional care and toxicological vigilance [36]. In diabetes and metabolic syndrome, agents such as berberine and optimized curcumin formulations can be used alongside lifestyle interventions and standard pharmacotherapy. These botanicals improve insulin sensitivity, modulate lipid metabolism, and reduce inflammation, but their use necessitates close monitoring of glycaemic control and potential drug interactions, especially with hypoglycaemic agents [37] In nonalcoholic fatty liver disease, silymarin and curcumin stand out as candidates with hepatoprotective and antifibrotic activity. However, treatment must include regular monitoring of hepatic enzymes and fibrosis progression, while ensuring that herbal products are free of hepatotoxic contaminants or adulterants [38].

Phytomedicines with antioxidant and mitochondrial-protective properties also have potential as prophylactic adjuncts in drug-induced organ injuries, including chemotherapy-related neuropathy and ischemia–reperfusion syndromes. These applications remain largely experimental and demand rigorous clinical trials [39]. For nephroprotection, flavonoids and saponins demonstrate promise in reducing experimental nephrotoxicity. Nevertheless, strict botanical authentication is essential to avoid nephrotoxic species such as Aristolochia, and all preparations should undergo heavy-metal screening [40]. Finally, neuroprotection and cardioprotection represent emerging frontiers. Clinical studies targeting high-risk contexts, such as perioperative ischemia or chemotherapy, could clarify translational value while establishing safe, evidence-based practice.

CONCLUSION

Herbal strategies hold genuine potential to prevent or mitigate metabolic and organ-specific disorders because of their multi-target biology. Realizing that potential safety requires toxicology to be integral, not peripheral, to research, regulation, and clinical practice. With standardized products, rigorous preclinical and clinical toxicology, targeted trials, and active surveillance, traditional medicines can be integrated into modern care as evidence-based adjuncts that complement, rather than substitute for, established therapies.

REFERENCES

1. Liheluka E, Gibore NS, Lusingu JPA, Gesase S, Minja DTR, Lamshöft M, Dekker D, Bali T. Community perceptions on the effectiveness of herbal medicines and factors associated with their use in managing diarrhoea among under-five children in North-eastern Tanzania. Trop Med Health. 2023 Aug 25;51(1):48. doi: 10.1186/s41182-023-00537-5. PMID: 37626395; PMCID: PMC10464464.
2. Agu, P. C., Christopher, N. N., Nwiziogo, F. C., Okafor, M. U., *et al.* (2025). Historical and ethnopharmacological perspectives on African medicinal plants: From traditional remedies to computational drug discovery. *Scientific African*, *30*, e02941. https://doi.org/10.1016/j.sciaf.2025.e02941
3. Syed, A., Elgorban, A.M., Bahkali, A.H. *et al.* Therapeutic Potential of products derived from *Pluchea lanceolata* for Alzheimer's Disease Treatment. *J Mol Neurosci* **75**, 122 (2025). https://doi.org/10.1007/s12031-025-02409-5
4. Ssenku, J.E., Okurut, S.A., Namuli, A. *et al.* Medicinal plant use, conservation, and the associated traditional knowledge in rural communities in Eastern Uganda. *Trop Med Health* **50**, 39 (2022). https://doi.org/10.1186/s41182-022-00428-1

5. Egba, SI., Ogbodo, JO., Ogbodo PO and Obike CA Toxicological Evaluation of Two Named Herbal Remedies Sold Across Orumba South Local Government of Anambra State, South-Eastern Nigeria. Asian Journal of Research in Biochemistry, 2017; 1(1):1-6
6. Kenneth C. Nwachukwu, Godwin S. Aloh, Simeon I. Egba, Solomon N. Ijioma, Lukman A. Alli, Kingsley C. Ugwuanyi, Blessing U. Onwuchekwa and Michael P. Okoh. Phytochemical composition, GC-MS analysis and toxicological profiling of *Gouania longipetala* leaf extract in rats Afr J Biotech. 2023; 22(9), 192-201. DOI: 10.5897/AJB2023.17594
7. Phua DH, Zosel A, Heard K. Dietary supplements and herbal medicine toxicities-when to anticipate them and how to manage them. Int J Emerg Med. 2009 Jun 10;2(2):69-76. doi: 10.1007/s12245-009-0105-z. PMID: 20157447; PMCID: PMC2700222.
8. Akwari, A.A., Okoroh, P.N., Aniokete, U.C., Abba, J.N., Uti, D.E. Phytochemicals as modulators of ferroptosis: a novel therapeutic avenue in cancer and neurodegeneration. *Mol Biol Rep* **52**, 636 (2025). https://doi.org/10.1007/s11033-025-10752-4
9. Saeed, E., Javed, F., Rana, Z., Perveen, R., Mallhi, I.Y., Amjad, I., Maqsood, Q., Chaudhary, N.A., Tahir, S.B., Fatima, A., Rasheed, N.F. Bioactive Compounds, Their Mechanisms of Action, and Cardioprotective Effects of Pomegranate (*Punica granatum*): A Comprehensive Review. eFood, 2025; 6:e70075https://doi.org/10.1002/efd2.70075
10. Ugwu, O.P.C., Kungu, E., Inyangat, R., Obeagu, E. I., Alum, E. U., Okon, M. B., Subbarayan, S. and Sankarapandiyan, V. Exploring Indigenous Medicinal Plants for Managing Diabetes Mellitus in Uganda: Ethnobotanical Insights, Pharmacotherapeutic Strategies, and National Development Alignment. INOSR Experimental Sciences.2023; 12(2):214-224. https://doi.org/10.59298/INOSRES/2023/2.17.1000.
11. Stalin A, Hesham AE, Mishra A, Zou Q, Ignacimuthu S. Editorial: Herbal medical products for metabolic diseases - new integrated pharmacological approaches. Front Pharmacol. 2024 Aug 9;15:1464176. doi: 10.3389/fphar.2024.1464176. PMID: 39185309; PMCID: PMC11341434.
12. Fan Y, Liu Y, Shao C, Jiang C, Wu L, Xiao J, Tang L. Gut Microbiota-Targeted Therapeutics for Metabolic Disorders: Mechanistic Insights into the Synergy of Probiotic-Fermented Herbal Bioactives. *International Journal of Molecular Sciences*. 2025; 26(12):5486. https://doi.org/10.3390/ijms26125486
13. Cui, D., Zhang, C., Zhang, L. *et al.* Natural anti-cancer products: insights from herbal medicine. *Chin Med* **20**, 82 (2025). https://doi.org/10.1186/s13020-025-01124-y
14. Uti DE, Atangwho IJ, Alum EU, Egba SI, Ugwu OPC, Ikechukwu GC. Natural Antidiabetic Agents: Current Evidence and Development Pathways from Medicinal Plants to Clinical use. Natural Product Communications. 2025;20(3). doi:10.1177/1934578x251323393
15. Ru, Q., Li, Y., Chen, L. *et al.* Iron homeostasis and ferroptosis in human diseases: mechanisms and therapeutic prospects. *Sig Transduct Target Ther* **9**, 271 (2024). https://doi.org/10.1038/s41392-024-01969-z
16. Olalekan, S.O., Bakare, O.O., Faponle, A.S. *et al.* A review of gut microbial metabolites and therapeutic approaches in hypertension. *Bull Natl Res Cent* **48**, 95 (2024). https://doi.org/10.1186/s42269-024-01252-9
17. Graf BL, Raskin I, Cefalu WT, Ribnicky DM. Plant-derived therapeutics for the treatment of metabolic syndrome. Curr Opin Investig Drugs. 2010 Oct;11(10):1107-15. PMID: 20872313; PMCID: PMC3755736.
18. Cefalu WT, Ye J, Zuberi A, Ribnicky DM, Raskin I, Liu Z, Wang ZQ, Brantley PJ, Howard L, Lefevre M. Botanicals and the metabolic syndrome. Am J Clin Nutr. 2008 Feb;87(2):481S-7S. doi: 10.1093/ajcn/87.2.481S. PMID: 18258643.
19. Gomes TM, Sousa P, Campos C, Perestrelo R, Câmara JS. Secondary Bioactive Metabolites from Foods of Plant Origin as *Theravention* Agents against Neurodegenerative Disorders. *Foods*. 2024; 13(14):2289. https://doi.org/10.3390/foods13142289
20. El-Saadony MT, Yang T, Korma SA, Sitohy M, Abd El-Mageed TA, Selim S, Al Jaouni SK, Salem HM, Mahmmod Y, Soliman SM, Mo'men SAA, Mosa WFA, El-Wafai NA, Abou-Aly HE, Sitohy B, Abd El-Hack ME, El-Tarabily KA, Saad AM. Impacts of turmeric and its principal bioactive curcumin on human health: Pharmaceutical, medicinal, and food applications: A comprehensive review. Front Nutr. 2023 Jan 10;9:1040259. doi: 10.3389/fnut.2022.1040259. PMID: 36712505; PMCID: PMC9881416.
21. Sharifi-Rad J, Rayess YE, Rizk AA, Sadaka C, Zgheib R, Zam W, Sestito S, Rapposelli S, Neffe-Skocińska K, Zielińska D, Salehi B, Setzer WN, Dosoky NS, Taheri Y, El Beyrouthy M, Martorell M, Ostrander EA, Suleria HAR, Cho WC, Maroyi A, Martins N. Turmeric and Its Major Compound Curcumin on Health: Bioactive Effects and Safety Profiles for Food, Pharmaceutical, Biotechnological and Medicinal Applications. Front Pharmacol. 2020 Sep 15;11:01021. doi: 10.3389/fphar.2020.01021. PMID: 33041781; PMCID: PMC7522354.

22. Anas, M., Falak, A., Khan, A. *et al.* Therapeutic potential and agricultural benefits of curcumin: a comprehensive review of health and sustainability applications. *J.Umm Al-Qura Univ. Appll. Sci.* (2024). https://doi.org/10.1007/s43994-024-00200-7
23. Tian, WW., Liu, L., Chen, P. *et al. Curcuma Longa* (turmeric): from traditional applications to modern plant medicine research hotspots. *Chin Med* **20**, 76 (2025). https://doi.org/10.1186/s13020-025-01115-z
24. Ahmed M. Targeting aging pathways with natural compounds: a review of curcumin, epigallocatechin gallate, thymoquinone, and resveratrol. Immun Ageing. 2025 Jul 3;22(1):28. doi: 10.1186/s12979-025-00522-y. PMID: 40611111; PMCID: PMC12225039.
25. Wu SK, Wang L, Wang F, Zhang J. Resveratrol improved mitochondrial biogenesis by activating SIRT1/PGC-1α signal pathway in SAP. Sci Rep. 2024 Oct 31;14(1):26216. doi: 10.1038/s41598-024-76825-9. PMID: 39482340; PMCID: PMC11528064.
26. Zheng M, Bai Y, Sun X, Fu R, Liu L, Liu M, Li Z, Huang X. Resveratrol Reestablishes Mitochondrial Quality Control in Myocardial Ischemia/Reperfusion Injury through Sirt1/Sirt3-Mfn2-Parkin-PGC-1α Pathway. *Molecules*. 2022; 27(17):5545. https://doi.org/10.3390/molecules27175545
27. Wang H, Chen Y, Wang L, Liu Q, Yang S, Wang C. Advancing herbal medicine: enhancing product quality and safety through robust quality control practices. Front Pharmacol. 2023 Sep 25;14:1265178. doi: 10.3389/fphar.2023.1265178. PMID: 37818188; PMCID: PMC10561302.
28. Alum, E. U. (2025). The role of toxicology in climate change: Understanding the risks of novel environmental toxins. *Sustainable Environment*, *11*(1). https://doi.org/10.1080/27658511.2025.2467485
29. Zhou Q, Jiang L, Su T, Liu G, Yang L. Overview of aristolochic acid nephropathy: an update. Kidney Res Clin Pract. 2023 Sep;42(5):579-590. doi: 10.23876/j.krcp.22.211. Epub 2023 Jun 15. PMID: 37448287; PMCID: PMC10565449.
30. Debelle FD, Nortier JL, De Prez EG, Garbar CH, Vienne AR, Salmon IJ, Deschodt-Lanckman MM, Vanherweghem JL. Aristolochic acids induce chronic renal failure with interstitial fibrosis in salt-depleted rats. J Am Soc Nephrol. 2002 Feb;13(2):431-436. doi: 10.1681/ASN.V132431. PMID: 11805172.
31. This dose-response complexity underlines the importance of carefully designed safety thresholds. Herb-drug interactions form another significant concern
32. Borse SP, Singh DP, Nivsarkar M. Understanding the relevance of herb-drug interaction studies with special focus on interplays: a prerequisite for integrative medicine. Porto Biomed J. 2019 Mar 1;4(2):e15. doi: 10.1016/j.pbj.0000000000000015. PMID: 31595257; PMCID: PMC6726296.
33. Gamil, N.M., Elsayed, H.A., Hamed, R.M. *et al.* Insights from herb interactions studies: a foundational report for integrative medicine. *Futur J Pharm Sci* **11**, 46 (2025). https://doi.org/10.1186/s43094-025-00794-7
34. Deodhar M, Al Rihani SB, Arwood MJ, Darakjian L, Dow P, Turgeon J, Michaud V. Mechanisms of CYP450 Inhibition: Understanding Drug-Drug Interactions Due to Mechanism-Based Inhibition in Clinical Practice. Pharmaceutics. 2020 Sep 4;12(9):846. doi: 10.3390/pharmaceutics12090846. PMID: 32899642; PMCID: PMC7557591.
35. Manjula, V.S., Uti, D.E., Echegu, D.A., Ugwu, O.P.C., Egba, S.I., Agu, P.C. Metabolomics-Driven Standardization of Herbal Medicine: Advances, Applications, and Sustainability Considerations. *Natural Product Communications*. 2025;20(8). doi:10.1177/1934578X251367650
36. Chugh NA, Bali S, Koul A. Integration of botanicals in contemporary medicine: road blocks, checkpoints and go-ahead signals. Integr Med Res. 2018 Jun;7(2):109-125. doi: 10.1016/j.imr.2018.03.005. Epub 2018 Mar 28. PMID: 29989061; PMCID: PMC6035497.
37. Rodríguez Villanueva J, Martín Esteban J, Rodríguez Villanueva L. Pharmacological Activities of Phytomedicines: A Challenge Horizon for Rational Knowledge. *Challenges*. 2018; 9(1):15. https://doi.org/10.3390/challe9010015
38. Achu Mosoh D. Recent Advances in Phytochemical Research for Cancer Treatment [Internet]. Biochemistry. IntechOpen; 2024. Available from: http://dx.doi.org/10.5772/intechopen.1007200
39. Hua, H., Tang, JY., Zhao, JN. *et al.* From traditional medicine to modern medicine: the importance of TCM regulatory science (TCMRS) as an emerging discipline. *Chin Med* **20**, 92 (2025). https://doi.org/10.1186/s13020-025-01152-8
40. Wen, H., Deng, H., Li, B. *et al.* Mitochondrial diseases: from molecular mechanisms to therapeutic advances. *Sig Transduct Target Ther* **10**, 9 (2025). https://doi.org/10.1038/s41392-024-02044-3

CITE AS: Waiswa Arajab (2026). Integrating Toxicology and Traditional Medicine: Herbal Strategies against Metabolic and Organ-Specific Disorders. RESEARCH INVENTION JOURNAL OF SCIENTIFIC AND EXPERIMENTAL SCIENCES 6(1):75-80. https://doi.org/10.59298/RIJSES/2026/617580